Ginkgo Bioworks, a.k.a. “the organism company,” has notched many milestones in its 13-year history, Fortune magazine reports. Founded by four Ph.D. students in bioengineering and computer science at MIT with their professor, the synthetic biology business has partnered with Fortune 500 giants to develop custom strains of organisms used to make everything from fragrances to fertilizers. They have collaborated with Roche to hunt for natural antibiotics in soil. They’ve worked with startups to engineer probiotics to treat disease and to break down plastic pollution. They’ve designed lab-grown proteins that make faux meat taste real. Now they share the story of taking their company public via a SPAC.
The company in May announced a business combination with Soaring Eagle Acquisition that values the engineered biology company at a $15 billion pre-money equity valuation and is expected to provide up to $2.5 billion of primary proceeds. Read more.
Related Posts
Getty Images Warrant Holders Win $88M in SPAC Deal Suit
It’s also liable for prejudgment interest in an amount still to be determined, the court ruled.
Alec Gores Aims to Shutter Trio of SPACs Early
Gores Holdings VII, the largest of the three, raised $550 million in February 2021, while Gores Technology Partners II pulled in $460 million and Gores Technology Partners gathered $275 million in March 2021. The SPACs plan to get shareholder approval to accelerate their liquidation sometime in December.
ATI Physical Therapy CEO Gone 2 Months After SPAC Merger: Report
The company late last month reported results below analysts expectations and cut full-year revenue projections by as much as 12 percent.
Regulatory Challenges to Allowing SPAC IPOs in Indonesia
Regardless of the benefits that a SPAC provides, the current regulatory framework in Indonesia presents several regulatory challenges that will need to be addressed before SPAC IPOs (and de-SPACs) can be implemented.